Skip to main content

United StatesBreaking News

Grafa

Cognition Therapeutics aligns with FDA on registrational path for lewy body dementia treatment

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company developing next-generation therapies for neurodegenerative disorders, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive update on its lead candidate, zervimesine (CT1812).

Read more
Grafa

Acumen Pharmaceuticals secures $35M for brain-delivery platform as Alzheimer’s trial reaches key milestone

Acumen Pharmaceuticals (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel targeted immunotherapy for Alzheimer’s disease, today reported financial results for the full year ended December 31, 2025, and provided a comprehensive business update.

Read more